ReviewProstate cancer and prostatic diseases2020
Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.
Review in Prostate cancer and prostatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03511664 (VISION), which is not on this map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Quantitative PSMA PET Biomarkers for Predicting Response toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Pooled it
- Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- 177Lutetium-PSMA-I&T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&T in Brazil.EJNMMI reports · 2026Article
- The role of multimodality imaging in selection, response assessment, and follow-up of patients receivingInsights into imaging · 2026Article
- Review
- Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer.Nature reviews. Urology · 2025Review
- Metabolic and imaging phenotypes associated withbioRxiv : the preprint server for biology · 2025Article
- PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who ReceivedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Article
- Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation.European journal of medical research · 2024Review
- Theranostic Robot-Assisted Radical Prostatectomy: Things Understood and Not Understood.Cancers · 2023Article
- A Novel Interaction between Chemokine and Phosphoinositide Signaling in Metastatic Prostate Cancer.Medical research archives · 2023Article
- An Overview of In Vitro Assays ofDiagnostics (Basel, Switzerland) · 2023Review
- TheranosticFrontiers in oncology · 2023Article
- Lutetium-177-PSMA-617: A Vision of the Future.Cancer biology & therapy · 2022Article
- PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study.Cancers · 2022Article
- Cyclotron Production of Gallium-68 Radiopharmaceuticals Using thePharmaceutics · 2022Review
- Pharmacological Optimization of PSMA-Based Radioligand Therapy.Biomedicines · 2022Review
- Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies.Molecules (Basel, Switzerland) · 2022Review
- Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.Molecular diagnosis & therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Theranostic principles utilize a molecular biomarker specific for a tumor target, initially for imaging to assess target expression and, if deemed suitable, for targeted therapy. This presents an exciting opportunity for a highly personalized treatment strategy in the era of precision medicine. Prostate-specific membrane antigen (PSMA) theranostics has attracted increasing attention as a promising targeted treatment in metastatic prostate cancer (PC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.